Encapsulated Cell Implant for Long-Term Intraocular Drug Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for vision-threatening disorders of the eye, such as glaucoma, retinitis pigmentosa, and age-related macular degeneration, face challenges in delivering therapeutic agents across the blood-retinal barrier and maintaining effective concentrations for extended periods without immunosuppression.

Innovation Solution

Implantation of a biocompatible capsule containing a cellular source of biologically active molecules, such as ARPE-19 cells, within the eye, surrounded by a semi-permeable membrane that allows diffusion of these molecules, providing therapeutically effective amounts for at least 12 months.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If transplantation procedures are used to deliver therapeutic agents to the eye, then the therapeutic effect is improved, but the need for long-term immunosuppression arises which is undesirable and expensive

Engineering Contradiction:

Improvetherapeutic effectVSAvoidimmunosuppression requirement

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The transplantation system is segmented into two functional components: (1) the cellular source of biologically active molecules that provides therapeutic effect, and (2) the semi-permeable membrane that selectively permits diffusion of therapeutic molecules while blocking immunological effectors. This segmentation allows the therapeutic function to be separated from the immunogenic cells, resolving the contradiction between achieving therapeutic effect and avoiding long-term immunosuppression.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The semi-permeable membrane acts as an intermediary barrier between the transplanted cells and the host immune system. It selectively allows passage of small molecular weight therapeutic agents (up to approximately 10,000 daltons) while blocking larger immunological effectors such as antibodies and immune cells. This intermediary structure enables sustained therapeutic delivery without triggering long-term immunosuppression requirements.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If therapeutic agents are delivered into the eye to treat vision-threatening disorders, then the treatment efficacy is improved, but the ability to maintain therapeutically effective concentrations for extended periods is compromised

Engineering Contradiction:

Improvetreatment efficacyVSAvoidmaintenance of effective concentration

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The encapsulated cellular source continuously produces and secretes biologically active molecules through the semi-permeable membrane over extended periods (at least 12 months). This continuous production and diffusion mechanism maintains therapeutically effective concentrations at the site of implantation without requiring repeated administrations, thereby resolving the contradiction between treatment efficacy and duration of action.

Inventive Principle:

Principle #20Continuity of useful action

3Object-affected harmful factors

If the blood-retinal barrier is present in the eye, then the eye is protected, but the delivery of therapeutic agents across the barrier becomes difficult

Engineering Contradiction:

Improveeye protectionVSAvoiddelivery of therapeutic agents

Core Design Contradiction:

Object-affected harmful factorsVSEase of operation

Solution Approach 1:

The semi-permeable membrane serves as an artificial intermediary delivery system that bypasses the blood-retinal barrier. By implanting the cellular source directly within the eye (intraocular implantation), the therapeutic molecules diffuse locally through the semi-permeable membrane into the surrounding ocular tissues, avoiding the need to cross the blood-retinal barrier from the systemic circulation. This local delivery mechanism resolves the contradiction between eye protection and ease of therapeutic agent delivery.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The approach effectively delivers biologically active molecules like CNTF to treat eye disorders, improving visual acuity, retinal thickness, and reducing degeneration, while avoiding the need for long-term immunosuppression.

Implementation Method 1

a semi-permeable membrane surrounding the core, wherein the membrane permits the diffusion of the biologically active molecule therethrough

Methodology Applied

Scientific EffectDiffusion: Diffusion

Data Source

PatentUS20260053738A1Use of encapsulated cell therapy for treatment of ophthalmic disorders

Publication Date: 2026.02.26 NEUROTECH USA INC

AI summary

Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and/or macular telangiectasia.